Skip to content

Study · Systematic review · 2025

20 results

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.

Li M, Lin H, Yang Q, Zhang X, Zhou Q, Shi J, Ge F

Sleep1 Apr 2025Cited by 32 (Europe PMC)

PMID39626095 (opens in a new tab)DOI10.1093/sleep/zsae280 (opens in a new tab)PepBankPUB-39626095
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In reviewed OSA patients, the tirzepatide AHI treatment difference was -21.86 events/hour (95% CI -25.93 to -17.79); its original estimate reference was unstated.

    In plain wordsIn reviewed sleep-apnea patients, tirzepatide had an AHI treatment difference of -21.86 events/hour; its original reference was unstated.

    Peptide
    Tirzepatide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Measurements

    Native AHI treatment difference
    −21.86 events/hour
    tirzepatide; 95% CI -25.93 to -17.79; original estimate reference unspecified

    Source sentences

    Summary
    Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI = -25.93 to -17.79) vs -5.10 events per hour (95% CI = -6.95 to -3.26).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.
  2. 02HumanSystematic reviewEfficacy outcome

    In reviewed OSA patients, the liraglutide AHI treatment difference was -5.1 events/hour (95% CI -6.95 to -3.26); its original estimate reference was unstated.

    In plain wordsIn reviewed sleep-apnea patients, liraglutide had an AHI treatment difference of -5.1 events/hour; its original reference was unstated.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Measurements

    Native AHI treatment difference
    −5.1 events/hour
    liraglutide; 95% CI -6.95 to -3.26; original estimate reference unspecified

    Source sentences

    Summary
    Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI = -25.93 to -17.79) vs -5.10 events per hour (95% CI = -6.95 to -3.26).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.
  3. 03HumanSystematic reviewEfficacy outcome

    In reviewed OSA patients, tirzepatide had greater AHI-reduction magnitude than liraglutide; the source reports separate estimates, not a direct head-to-head effect coefficient.

    In plain wordsIn reviewed sleep-apnea patients, tirzepatide had greater breathing-interruption reduction than liraglutide; no direct-comparison coefficient was stated.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMagnitude of AHI reduction compared with the other native drug
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI = -25.93 to -17.79) vs -5.10 events per hour (95% CI = -6.95 to -3.26).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.
  4. 04HumanSystematic reviewEfficacy outcome

    In reviewed OSA patients, liraglutide had smaller AHI-reduction magnitude than tirzepatide; the source reports separate estimates, not a direct head-to-head effect coefficient.

    In plain wordsIn reviewed sleep-apnea patients, liraglutide had smaller breathing-interruption reduction than tirzepatide; no direct-comparison coefficient was stated.

    Peptide
    Liraglutide
    Outcome
    DecreaseMagnitude of AHI reduction compared with the other native drug
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide significantly reduced AHI more than liraglutide with an estimated treatment difference of -21.86 events per hour (95% CI = -25.93 to -17.79) vs -5.10 events per hour (95% CI = -6.95 to -3.26).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In reviewed OSA patients, pooled GLP-1RA treatment had an AHI difference of -9.48 events/hour (95% CI -12.56 to -6.40; I2=92%); the exact reference was unstated.

    In plain wordsIn reviewed sleep-apnea patients, pooled GLP-1 treatment had an AHI difference of -9.48 events/hour; the reference was unstated.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n = 1,067

    Outcome group
    Sleep · Sleep

    Measurements

    AHI treatment difference
    −9.48 events/hour
    pooled GLP-1RA treatment; 95% CI -12.56 to -6.40; I2=92%; reference unspecified
    Heterogeneity I2
    92%
    AHI treatment effect

    Source sentences

    Summary
    GLP-1RA significantly decreased AHI with an estimated treatment difference of -9.48 events per hour (95% confidence interval [CI] =  -12.56 to - 6.40, I2 = 92%).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In reviewed OSA patients, pooled GLP-1RA treatment had an AHI difference of -9.48 events/hour (95% CI -12.56 to -6.40; I2=92%); the exact reference was unstated.

    In plain wordsIn reviewed sleep-apnea patients, pooled GLP-1 treatment had an AHI difference of -9.48 events/hour; the reference was unstated.

    Peptide
    Tirzepatide
    Outcome
    DecreaseApnea-hypopnea index
    Study

    n = 1,067

    Outcome group
    Sleep · Sleep

    Measurements

    AHI treatment difference
    −9.48 events/hour
    pooled GLP-1RA treatment; 95% CI -12.56 to -6.40; I2=92%; reference unspecified
    Heterogeneity I2
    92%
    AHI treatment effect

    Source sentences

    Summary
    GLP-1RA significantly decreased AHI with an estimated treatment difference of -9.48 events per hour (95% confidence interval [CI] =  -12.56 to - 6.40, I2 = 92%).
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed weight by -10.99 kg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed weight by -10.99 kg.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −10.99 kg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The change in weight was -10.99 kg and body mass index (BMI) was -1.60 kg/m2.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed weight by -10.99 kg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed weight by -10.99 kg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight change
    −10.99 kg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The change in weight was -10.99 kg and body mass index (BMI) was -1.60 kg/m2.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed body mass index by -1.60 kg/m2.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed body mass index by -1.60 kg/m2.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Body mass index change
    −1.6 kg/m2
    GLP-1 receptor agonists

    Source sentences

    Summary
    The change in weight was -10.99 kg and body mass index (BMI) was -1.60 kg/m2.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 10HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed body mass index by -1.60 kg/m2.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed body mass index by -1.60 kg/m2.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Body mass index change
    −1.6 kg/m2
    GLP-1 receptor agonists

    Source sentences

    Summary
    The change in weight was -10.99 kg and body mass index (BMI) was -1.60 kg/m2.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed systolic blood pressure by -4.81 mmHg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed systolic blood pressure by -4.81 mmHg.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Systolic blood pressure mean difference
    −4.81 mmHg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The mean difference in systolic blood pressure was -4.81 mmHg and in diastolic blood pressure was -0.32 mmHg.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 12HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed systolic blood pressure by -4.81 mmHg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed systolic blood pressure by -4.81 mmHg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Systolic blood pressure mean difference
    −4.81 mmHg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The mean difference in systolic blood pressure was -4.81 mmHg and in diastolic blood pressure was -0.32 mmHg.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  9. 13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed diastolic blood pressure by -0.32 mmHg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed diastolic blood pressure by -0.32 mmHg.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Diastolic blood pressure mean difference
    −0.32 mmHg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The mean difference in systolic blood pressure was -4.81 mmHg and in diastolic blood pressure was -0.32 mmHg.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 14HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In this meta-analysis of people with obstructive sleep apnea, GLP-1 receptor agonists as a class changed diastolic blood pressure by -0.32 mmHg.

    In plain wordsIn people with sleep apnea, GLP-1 drugs as a class changed diastolic blood pressure by -0.32 mmHg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    Diastolic blood pressure mean difference
    −0.32 mmHg
    GLP-1 receptor agonists

    Source sentences

    Summary
    The mean difference in systolic blood pressure was -4.81 mmHg and in diastolic blood pressure was -0.32 mmHg.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  11. 15HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In reviewed OSA patients, the obesity subgroup had greater AHI-reduction magnitude than an unnamed comparison subgroup (reported differences -12.93 versus -4.31 events/hour).

    In plain wordsIn reviewed sleep-apnea patients, the obesity subgroup had greater breathing-interruption reduction than an unnamed comparison subgroup.

    Peptide
    Liraglutide
    Outcome
    IncreaseMagnitude of AHI reduction in obesity subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Measurements

    AHI treatment difference
    −12.93 events/hour
    obesity subgroup; original effect-estimate reference unspecified
    AHI treatment difference
    −4.31 events/hour
    unnamed comparison subgroup; original effect-estimate reference unspecified

    Source sentences

    Summary
    Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of -12.93 events per hour vs -4.31 events per hour.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  12. 16HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In reviewed OSA patients, the obesity subgroup had greater AHI-reduction magnitude than an unnamed comparison subgroup (reported differences -12.93 versus -4.31 events/hour).

    In plain wordsIn reviewed sleep-apnea patients, the obesity subgroup had greater breathing-interruption reduction than an unnamed comparison subgroup.

    Peptide
    Tirzepatide
    Outcome
    IncreaseMagnitude of AHI reduction in obesity subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Measurements

    AHI treatment difference
    −12.93 events/hour
    obesity subgroup; original effect-estimate reference unspecified
    AHI treatment difference
    −4.31 events/hour
    unnamed comparison subgroup; original effect-estimate reference unspecified

    Source sentences

    Summary
    Obese individuals experienced a more significant decrease in AHI with an estimated treatment difference of -12.93 events per hour vs -4.31 events per hour.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  13. 17HumanNot a test of Liraglutide aloneSystematic reviewOther

    In reviewed OSA studies, continuous positive airway pressure use did not affect the pooled GLP-1RA therapeutic effect; statistical tests were unstated.

    In plain wordsIn reviewed sleep-apnea studies, CPAP use did not affect the pooled GLP-1 treatment effect; statistical tests were unstated.

    Peptide
    Liraglutide
    Outcome
    Not applicableEffect modification by continuous positive airway pressure
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The application of continuous positive airway pressure and the duration of follow-up did not affect the therapeutic effect.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  14. 18HumanNot a test of Tirzepatide aloneSystematic reviewOther

    In reviewed OSA studies, continuous positive airway pressure use did not affect the pooled GLP-1RA therapeutic effect; statistical tests were unstated.

    In plain wordsIn reviewed sleep-apnea studies, CPAP use did not affect the pooled GLP-1 treatment effect; statistical tests were unstated.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEffect modification by continuous positive airway pressure
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The application of continuous positive airway pressure and the duration of follow-up did not affect the therapeutic effect.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  15. 19HumanNot a test of Liraglutide aloneSystematic reviewOther

    In reviewed OSA studies, follow-up duration did not affect the pooled GLP-1RA therapeutic effect; statistical tests were unstated.

    In plain wordsIn reviewed sleep-apnea studies, follow-up length did not affect the pooled GLP-1 treatment effect; statistical tests were unstated.

    Peptide
    Liraglutide
    Outcome
    Not applicableEffect modification by follow-up duration
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The application of continuous positive airway pressure and the duration of follow-up did not affect the therapeutic effect.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  16. 20HumanNot a test of Tirzepatide aloneSystematic reviewOther

    In reviewed OSA studies, follow-up duration did not affect the pooled GLP-1RA therapeutic effect; statistical tests were unstated.

    In plain wordsIn reviewed sleep-apnea studies, follow-up length did not affect the pooled GLP-1 treatment effect; statistical tests were unstated.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEffect modification by follow-up duration
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    The application of continuous positive airway pressure and the duration of follow-up did not affect the therapeutic effect.
    4 context sentences
    Summary · context
    We conducted a meta-analysis to evaluate the effect of GLP-1RA intervention in OSA individuals.
    Summary · context
    We searched the PubMed and Web of Science databases (published until July 1, 2024).
    Summary · context
    The included studies evaluated the GLP-1RA in OSA individuals and the efficacy outcomes measured by the apnea-hypopnea index (AHI).
    Summary · context
    Six studies with a total of 1067 participants enrolled.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07207148

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Northwestern Universityn = 10015 Nov 2025 to est. 31 Aug 2028

Multiple Sclerosis

Trial pageClinicalTrials.govUpdated 17 Mar 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.